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Introduction
Multiple myeloma (MM) is a lymphoid cancer of terminally differentiated B-cell lineage or plasma cells that accounts for 10% of all hematologic cancers 1 , ranking as the second most common blood cancer, after non-Hodgkin lymphoma 2 . MM, currently an incurable disease, is characterized as a tumor composed of long-surviving rather than fast-growing malignant plasma cells 3, 4 . This implies that a therapeutic potential may lie in potentiating apoptosis.
Synthetic alkyl-lysophospholipids (ALPs) constitute a heterogeneous group of unnatural lipids with promising anticancer activity. Unlike most conventional chemotherapeutic drugs, ALPs do not target the DNA, but act at the level of cell membranes affecting apoptotic signaling [5] [6] [7] . The prototype of these ALPs is 1-Ooctadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH 3 , edelfosine) that shows selective apoptosis in tumor cells, whereas normal cells are spared 8 . Examples of clinically relevant oral anti-cancer ALPs include the prototypic compound edelfosine and the novel drug octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate (D-21266, perifosine) 5, 9 . We have found that edelfosine induces selectively apoptosis in leukemic cells by its preferential incorporation into cancer cells 8, 10, 11 , leading to the intracellular activation of the death receptor Fas/CD95 by its recruitment together with downstream signaling molecules into clusters of lipid rafts [10] [11] [12] . This edelfosine-induced Fas/CD95 intracellular activation and concentration in lipid rafts was independent of its ligand Fas/CD95 ligand (FasL/CD95L) and did not require sphingomyelinase activation 10, 11 .
Edelfosine was the first antitumor drug reported to act through a novel mechanism involving Fas/CD95 translocation into lipid rafts 12 , and recent findings further support that co-clustering of Fas/CD95 with lipid rafts is a novel and efficient mode of inducing apoptosis in cancer chemotherapy [11] [12] [13] [14] [15] [16] [17] .
Fas/CD95 shares with other death receptors of the tumor necrosis factor (TNF)
receptor superfamily, such as TNF-related apoptosis-inducing ligand (TRAIL) receptors, the capacity to transmit apoptosis signals through the presence of a death domain in its cytoplasmic portion after receptor engagement with its ligand or an agonistic antibody 18 . Unlike the intracellular regions of other transmembrane receptors involved in signal transduction, the death domain does not possess enzymatic activity, but mediates signaling through protein-protein interactions. Stimulation of Fas/CD95 results in receptor aggregation and recruitment of the adaptor molecule Fas-associated death domain-containing protein (FADD) through interaction between its own death domain and the clustered receptor death domains. FADD, in turn, contains a death effector domain that binds to an analogous domain repeated in tandem within the zymogen form of procaspase-8, forming the so-called death-inducing signaling complex (DISC), made up of aggregated Fas, FADD and procaspase-8 19 . Upon recruitment by FADD, procaspase-8 oligomerization drives its activation through self-cleavage, activating downstream effector caspases and leading to apoptosis. We and others have recently reported that Fas is translocated into lipid raft clusters during Fas-mediated apoptosis [10] [11] [12] 16, 17, [20] [21] [22] . Thus, aggregation of membrane platforms where Fas molecules are brought together is suggested to facilitate DISC formation and thereby potentiate
Fas signaling [10] [11] [12] 16, 17, [20] [21] [22] [23] . Lipid rafts are membrane microdomains highly enriched in cholesterol and sphingolipids varying in size from 50-70 nm, and the proteins located in these microdomains are severely limited in their ability to freely diffuse over the plasma membrane 24 . Thus, raft association tends to concentrate specific proteins within plasma membrane microdomains, affecting protein function 25 .
Because ALPs are potent apoptotic inducers in cancer cells and MM is a slowly proliferating tumor of long-lived plasma cells, we reasoned that this disease could be particularly suitable for the therapeutic use of ALPs. Thus, we investigated the action of ALPs on MM and analyzed the role of death receptor and lipid raft co-clustering in their antimyeloma action.
Materials and Methods

Reagents
Edelfosine was from INKEYSA (Barcelona, Spain). Perifosine was from Zentaris (Frankfurt, Germany). RhTRAIL and rhFasL were from Alexis Biochemicals (Lausen, Switzerland). All other chemicals were from Sigma Chemical (St Louis, MO), Roche Biochemicals (Mannheim, Germany) or Merck (Darmstadt, Germany). following the manufaturer's directions.
Cell lines and primary cells
Human umbilical vein endothelial cells were obtained by collagenase digestion of umbilical cord veins as described 27 .
Immunofluorescence flow cytometry
Cell surface expression of death receptors was analyzed by flow cytometry in 4 x 10 5 cells as described previously 10, 28 
Confocal microscopy
Cells were settled onto poly-L-lysine-coated slides and analyzed with a Zeiss LSM 510 laser scan confocal microscope (Oberkochen, Germany) for membrane raft and protein visualization as described 12 . Co-localization assays were analyzed by excitation of the corresponding fluorochromes in the same section. Negative controls, lacking the primary antibody or using an irrelevant antibody, showed no staining.
Apoptosis assay
Quantitation of apoptotic cells was calculated by flow cytometry as the percentage of cells in the sub-G 1 region (hypodiploidy) in cell cycle analysis as previously described 29 .
The implication of Fas/CD95-FasL/CD95L interaction in ALP-induced apoptosis was evaluated as previously described 10 . Cells (2. immunoglobulins had no effect.
Edelfosine uptake
Drug uptake was measured as described previously 8 
Lipid raft isolation and Western blotting
Lipid rafts were isolated by using lysis conditions and centrifugation on discontinuous sucrose gradients as previously reported 12 
Coimmunoprecipitation
MM144 cells (3-6 x 10 7 ) were lysed with 500 L of lysis buffer (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.9% Triton X-100, 10% glycerol, 2 mM Na 3 VO 4 , 2 mM PMSF).
Lysates were precleared with protein A-Sepharose, and immunoprecipitated with antiFas (C-20) rabbit polyclonal antibody precoupled to protein A-Sepharose as previously described 31 . Samples were subjected to SDS-PAGE and immunoblotted with specific antibodies against FADD and caspase-8. To immunoprecipate membrane raft proteins, fractions 4-6 (200 l each) from the lipid raft isolation sucrose gradient were pooled and used for the coimmunoprecipitation assay as above. Lysates and membrane raft pools were also immunoprecipitated with P3X63 myeloma supernatant or with rabbit nonrevelant IgG that was isolated from pooled normal nonimmune rabbit serum, as negative controls, showing no signal.
Cholesterol depletion and sequestration
For cholesterol depletion, 2.5 x 10 5 cells/mL were pretreated with 2.5 mg/mL methyl-β-cyclodextrin (MCD) for 30 min at 37ºC in serum-free medium. Cells were then washed three times with PBS and resuspended in complete culture medium before ALP addition. For cholesterol sequestration, cells were treated with 0.3 μg/mL filipin for 1 h at 37ºC in serum-free medium, and then processed as above.
Retroviral gene expression of Fas/CD95
Construction of retroviral vectors
Human Fas/CD95 and a 57 COOH-terminally truncated Fas/CD95 mutant (FasΔ57C) were cloned into the pLNCX2 retroviral vector (BD Biosciences Clontech, Palo Alto, CA) at the XhoI and SalI sites of the multiple cloning site. The resulting constructs were transformed to Escherichia coli DH5α cells. These constructs, as well as the empty vector, pLNCX2, were used in the subsequent transfection experiments.
Transfection of the packaging cell line
On the day before transfection the retroviral packaging cell line PT67 was plated on 60 mm-diameter plates ( After mixing, 250 μL of 2 x Hepes-buffered saline solution (pH 7.0) was added by bubbling, and the resulting solution was immediately dropped onto cells. The cells were then returned to the 37ºC incubator (5% CO 2 ) for 24 h. Subsequently, the medium was changed to 3 mL of fresh culture medium containing 10% FBS, and 24-72 h later, the supernatant from transfected cells was centrifuged at 1000 x g for 5 min in a Sorvall T6000D centrifuge.
Infection of MM cells
The target Fas/CD95-deficient OPM-2 cells were plated 12-18 h before infection at a cell density of 1-2 x 10 5 /60 mm-diameter plate in RPMI-1640/10% FBS. For infection, the medium from the retroviral packaging PT67 cells was collected and filtered through a 0.45-µm cellulose acetate sterile filter. Target cells were infected with 1 mL viral supernatant containing Polybrene at 8 μg/mL for 1 h. RPMI-1640/10% FBS medium (8 mL) was added, and cells were grown for 24 h and then exposed to another round of infection. After the second round of infection, cells were grown for 2 to 3 days before selection with 400 μg/mL G418.
Cell transfection with Bcl-X L
The were subjected to electroporation at 500 V, 1700 µF, 72 ohm in a BTX electro cell manipulator 600 (Biotechnologies & Experimental Research Inc., SanDiego, CA), and selected by growth in the presence of 400 μg/mL of G418.
Mitochondrial cytochrome c release
Release of cytochrome c from mitochondria to cytosol was analyzed by Western blot as described previously 32 , using antibodies against cytochrome c (7H8.2C12; BD Pharmingen, San Diego, CA) and cytochrome oxidase subunit II (12C4-F12; Molecular Probes, Eugene, OR).
Results
Edelfosine and perifosine induce selectively apoptosis in MM cells
We found that the ALPs edelfosine and perifosine induced a potent apoptotic response in different MM cell lines ( Figure 1A ). There was a good correlation between the cell Normal cells, including normal PBLs as well as normal purified B and T cells from healthy volunteers, were not affected by these drugs ( Figure 1D ). However, T lymphoid
Jurkat and B lymphoid JY leukemic cells were very sensitive to the apoptotic action of ALPs ( Figure 1D ). In addition, normal human umbilical vein endothelial cells were also spared by these drugs (data not shown).
Clustering of Fas/CD95 in lipid rafts is crucial to ALP-induced apoptosis in MM cells
Following a time-course analysis we found that edelfosine and perifosine induced an apoptotic response in MM144 cells after about 15 h of incubation ( Figure 2A ). This effect was rather slow when compared to the rapid triggering of apoptosis following edelfosine treatment in T lymphoid Jurkat cells (>20% apoptosis after 6 h-incubation) 33 . This timing in the induction of apoptosis was further corroborated by caspase-3 activation in edelfosine-treated MM144 cells, as assessed by cleavage of procaspase-3 into the p18 active form and cleavage of the typical caspase-3 substrate poly(ADPribose) polymerase (PARP), using a polyclonal anti-caspase-3 antibody that recognized the 18-kDa subunit of active caspase-3, and an anti-PARP monoclonal antibody that detected both the 116-kDa intact form and the 85-kDa cleaved form of PARP ( Figure   2B ). 
ALP-induced translocation of death receptors and downstream signaling molecules into lipid rafts
The above Fas/CD95 and lipid raft co-clustering was further confirmed by isolation of membrane rafts from MM144 cells, untreated and treated with either edelfosine or perifosine ( Figure 4A ). Lipid rafts were isolated based on their insolubility in Triton X-100 lysis buffer at 4ºC and fractionated by discontinuous sucrose gradient centrifugation 11, 30 . GM1-containing lipid rafts, at the upper part (fractions 4-6) of the sucrose gradient ( Figure 4A ), were located using CTx B subunit conjugated to horseradish peroxidase 30 .
In addition to Fas/CD95, we also found that TRAIL receptors, DR4 and DR5, were translocated into lipid rafts in both edelfosine-and perifosine-treated cells ( Figure 4A ).
Death receptor downstream signaling molecules FADD and procaspase-8 were also translocated into membrane rafts ( Figure 4A ). Interestingly, a portion of the active cleaved caspase-8 forms were also found in lipid rafts following ALP treatment ( Figure   4A ). Our results indicate that edelfosine and perifosine induce a reorganization of the lipid raft protein content, translocating apoptotic proteins to these detergent-insoluble membrane domains. These data also show that the constituents of the DISC, the major apoptotic complex in death receptor signaling, are translocated into lipid rafts. This suggests that lipid rafts become enriched in apoptotic signaling molecules in ALPtreated MM cells, harboring and bringing together major components of the death receptor extrinsic pathway of apoptosis. We also found that Bid, which acts as a bridge between Fas/CD95 signaling and mitochondria 37, 38 , was translocated into lipid rafts following treatment of MM144 cells with edelfosine or perifosine ( Figure 4A) . A timecourse analysis showed that the translocation of the above proteins into lipid rafts occurred after 12-15 h incubation with the drugs (data not shown), i.e. by the time apoptosis was triggered ( Figure 2A ). We observed that edelfosine was more potent than perifosine in its ability to recruit apoptotic molecules into membrane rafts ( Figure 4A ).
This differential protein translocating activity of the ALPs might explain the higher antitumor activity of edelfosine when compared to perifosine in MM cells (Figure 1, A and C). It is noteworthy to highlight the almost complete translocation of Fas/CD95, DR5, FADD and Bid to lipid rafts following edelfosine treatment ( Figure 4A ).
Edelfosine induces DISC formation
Because 
Fas/CD95 is required for ALP-induced apoptosis
To further investigate the relevance of Fas/CD95 in ALP-mediated apoptosis in MM cells, we used an OPM-2 subline lacking Fas/CD95 ( Figure 1A) , that was generated after protacted cultures of parental OPM-2 cells. Fas/CD95-deficient OPM-2 cells expressed DR4 and DR5 at similar levels as the parental OPM-2 cells ( Figure 5A ), but were ALP-resistant ( Figure 1A ). This resistance was not due to a deficiency in drug 
Involvement of mitochondria in ALP-induced apoptosis in MM cells
Because Bid was translocated into lipid rafts in ALP-treated cells and edelfosinemediated apoptosis has been found to be dependent on mitochondrial signaling 29 
ALP-induced apoptosis in MM cells is independent of FasL/CD95L
Because Fas/CD95 was critical for the apoptotic effect of edelfosine and perifosine, we and TRAIL receptors in lipid rafts following cancer chemotherapy 15, 44 .
The concentration of death receptors in lipid rafts following ALP treatment rendered MM cells more sensitive to the action of death receptor ligands. This is of particular importance for TRAIL, as this ligand shows a promising and selective antitumor action in different cancer cells 45 as well as antimyeloma activity 46, 47 . Thus, our findings indicate that edelfosine and perifosine are not only effective in the killing of MM cells, but they might be valuable drugs in combination therapy. In addition, MM1R cells, that showed resistance to dexamethasone treatment, were readily killed by these ALPs, suggesting that these agents could circumvent drug resistance in MM.
Edelfosine has been shown to induce cell killing in MM cells resistant to doxorubicin, melphalan, mitoxantrone, VP-16, cytoxan, and vincristine 48 , and perifosine has been reported to be cytotoxic to MM cells resistant to dexamethasone and melphalan 49 . In addition, ALPs have been shown to be effective antitumor drugs in mouse MM models 49, 50 .
A remarkable finding of the current study is that ALPs killed malignant MM 
